FXR is downregulated in hepatocellular carcinoma and cholangiocarcinoma [86, 87], whereas there is experimental evidence suggesting that FXR activation reduces the carcinogenic potential in both types of cancers (the reader is referred to recent, comprehensive reviews on this topic, [88, 89]). The gene discussed is NR1H4; the disease is cancer.